RVMD Quote, Financials, Valuation and Earnings

Insmed, Inc. has a net margin of -- compared to Revolution Medicines, Inc.'s net margin of -124.5%. Revolution Medicines, Inc.'s return on equity of -59.94% beat Insmed, Inc.'s return on equity of -192.35%.

Revolution Medicines, Inc. has a consensus price target of $127.47, signalling upside risk potential of 22.52%. On the other hand Insmed, Inc. has an analysts' consensus of $212.53 which suggests that it could grow by 41.68%. Given that Insmed, Inc. has higher upside potential than Revolution Medicines, Inc., analysts believe Insmed, Inc. is more attractive than Revolution Medicines, Inc..

Revolution Medicines, Inc. has a beta of 1.006, which suggesting that the stock is 0.593% more volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.105, suggesting its more volatile than the S&P 500 by 10.538%.

Revolution Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revolution Medicines, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.

Revolution Medicines, Inc. quarterly revenues are --, which are smaller than Insmed, Inc. quarterly revenues of $263.8M. Revolution Medicines, Inc.'s net income of -$364.9M is lower than Insmed, Inc.'s net income of -$328.5M. Notably, Revolution Medicines, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revolution Medicines, Inc. is -- versus 49.20x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -- compared to Revolution Medicines, Inc.'s net margin of 34.4%. Revolution Medicines, Inc.'s return on equity of -59.94% beat Eli Lilly & Co.'s return on equity of 104.39%.

Revolution Medicines, Inc. has a consensus price target of $127.47, signalling upside risk potential of 22.52%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,214.34 which suggests that it could grow by 18.82%. Given that Revolution Medicines, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Revolution Medicines, Inc. is more attractive than Eli Lilly & Co..

Revolution Medicines, Inc. has a beta of 1.006, which suggesting that the stock is 0.593% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.

Revolution Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.61% to investors and pays a quarterly dividend of $1.73 per share. Revolution Medicines, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Revolution Medicines, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Revolution Medicines, Inc.'s net income of -$364.9M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Revolution Medicines, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 45.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revolution Medicines, Inc. is -- versus 14.28x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -- compared to Revolution Medicines, Inc.'s net margin of 18.15%. Revolution Medicines, Inc.'s return on equity of -59.94% beat Merck & Co., Inc.'s return on equity of 36.76%.

Revolution Medicines, Inc. has a consensus price target of $127.47, signalling upside risk potential of 22.52%. On the other hand Merck & Co., Inc. has an analysts' consensus of $126.00 which suggests that it could grow by 5.62%. Given that Revolution Medicines, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Revolution Medicines, Inc. is more attractive than Merck & Co., Inc..

Revolution Medicines, Inc. has a beta of 1.006, which suggesting that the stock is 0.593% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.280, suggesting its less volatile than the S&P 500 by 72.042%.

Revolution Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.75% to investors and pays a quarterly dividend of $0.85 per share. Revolution Medicines, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Revolution Medicines, Inc. quarterly revenues are --, which are smaller than Merck & Co., Inc. quarterly revenues of $16.3B. Revolution Medicines, Inc.'s net income of -$364.9M is lower than Merck & Co., Inc.'s net income of $3B. Notably, Revolution Medicines, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 16.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revolution Medicines, Inc. is -- versus 4.61x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Travere Therapeutics, Inc. has a net margin of -- compared to Revolution Medicines, Inc.'s net margin of -16.95%. Revolution Medicines, Inc.'s return on equity of -59.94% beat Travere Therapeutics, Inc.'s return on equity of -80.28%.

Revolution Medicines, Inc. has a consensus price target of $127.47, signalling upside risk potential of 22.52%. On the other hand Travere Therapeutics, Inc. has an analysts' consensus of $42.7143 which suggests that it could grow by 43.58%. Given that Travere Therapeutics, Inc. has higher upside potential than Revolution Medicines, Inc., analysts believe Travere Therapeutics, Inc. is more attractive than Revolution Medicines, Inc..

Revolution Medicines, Inc. has a beta of 1.006, which suggesting that the stock is 0.593% more volatile than S&P 500. In comparison Travere Therapeutics, Inc. has a beta of 0.827, suggesting its less volatile than the S&P 500 by 17.33%.

Revolution Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Travere Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revolution Medicines, Inc. pays -- of its earnings as a dividend. Travere Therapeutics, Inc. pays out -- of its earnings as a dividend.

Revolution Medicines, Inc. quarterly revenues are --, which are smaller than Travere Therapeutics, Inc. quarterly revenues of $129.7M. Revolution Medicines, Inc.'s net income of -$364.9M is lower than Travere Therapeutics, Inc.'s net income of -$22M. Notably, Revolution Medicines, Inc.'s price-to-earnings ratio is -- while Travere Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revolution Medicines, Inc. is -- versus 5.61x for Travere Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.